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The microRNA-200 family is known to be a master regulator of the epithelial-
to-mesenchymal transition, partially through its double-negative feedback loop with 
the transcriptional repressor Zeb1, yet the mechanisms on how miR-200 controls the 
invasive phenotype are not fully understood. Recent studies have shown that the 
miR-200/Zeb1 axis regulates cell-cell and cell-matrix interactions, but it has also 
been demonstrated that cell-intrinsic changes are insufficient to drive cancer cell 
invasion, leading us to focus on specific cell-matrix interactions required to activate 
tumor cell invasion and metastases.  We have shown through 3D studies that the 
Integrin β1-collagen I contact is critical in mediating the invasive phenotype in cells 
with miR-200 loss or Zeb1 overexpression. Furthermore, those genetic changes 
enhanced the cells responsiveness to the ECM through the FAK/Src pathway.  The 
importance of this pathway in our Kras and p53 mouse model and in human lung 
cancer cell lines was further studied using pharmacological inhibitors and an shRNA-
based knockdown approach, which exhibited a significant suppression of migration 
and invasion in Boyden chambers and 3D invasion assays. Furthermore, 
pharmacological inhibition of Src prevented distant metastases in vivo. We found 
vi 
 
that miR-200 regulates the activation of the FAK/Src pathway through direct 
targeting of CRKL, an integrin adaptor molecule. Our studies suggest that CRKL is 
critical in enhancing the outside-in signaling through Itgβ1 but also involved in the 
inside-out signaling by maintaining the cell-matrix contact required for continuous 
cell invasion. Those findings highlight the importance of the ECM composition, in 
addition to cell-intrinsic changes, that regulate the activation of intracellular signaling 
pathways required for tumor cell invasion and metastases that allow for targeting at 
multiple levels.  
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 Chapter 1 
Introduction 
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Lung cancer 
Lung cancer is a heterogeneous disease that is divided into two main types, 
non-small cell lung cancer (NSCLC, ~ 80-85 %) and small cell lung cancer (~15-20 
%). NSCLC can be further classified into adenocarcinoma, squamous carcinoma, 
large cell carcinoma, bronchoalveolar lung cancer and mixed types [1]. Lung cancer 
is listed as the second cancer type in the number of new estimated cases in both 
men and women and the leading cause of all cancer-related deaths, accounting for 
160,000 deaths per year in the United States. This can be explained by the fact that 
almost 2/3 of the patients when they first present already have metastatic disease, 
which has a 5 year survival rate of less than 5 % and has not changed over the past 
decades [2]. Understanding the molecular mechanisms underlying metastasis is 
therefore crucial in developing better treatment strategies. In order to study 
metastasis, a mouse model was previously developed in which mice carrying a 
somatic activation of the KrasG12D allele will develop lung adenocarcinoma but not 
metastasize. Introduction of the mutant p53 allele (p53R172HΔG), commonly found in 
Li-Fraumeni syndrome, into those mice causes the development of atypical 
adenomatous hyperplasia, adenomas and adenocarcinomas. The lung 
adenocarcinomas found in this model are highly metastatic, with metastases found 
at sites commonly seen in NSCLC patients. Transcriptional profiling of the tumors 
derived from this mouse model revealed a metastases signature that correlated with 
a subset of NSCLC patients with poor prognosis [3, 4].  
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Metastases and epithelial-to-mesenchymal transition  
Metastasis is a complex, multi-step process, in which cancer cells 
disseminate from the primary tumor by invasion into the surrounding ECM, 
intravasate, are transported through the blood circulation and extravasate from the 
blood vessels at distant organs, where they can form secondary tumors through 
establishment of micro-metastases, allowing for a rapid spread of cancer cells [5]. It 
is thought that cancer cells typically undergo an epithelial-to-mesenchymal transition 
(EMT) in order to gain migratory and invasive properties. Epithelial cells, found in the 
primary tumor, are characterized by tight junctions and an apical-basal polarity, and 
their cobble-stone like organization. Mesenchymal cells show an increased 
expression of mesenchymal markers, such as N-cadherin, ZEB1/2 and vimentin, 
allowing for increased motility through a decrease in cell-cell contact, displayed by 
their scattered, fibroblast-like appearance [6-8].  The transcriptional repressors ZEB1 
and ZEB2 have been shown to regulate EMT by suppressing the transcription of 
epithelial markers such as E-cadherin by binding to the E-boxes in the promoter 
region [9]. Furthermore, the invasive phenotype that tumor cells acquire upon 
metastasis is characterized by a reorganization of the actin cytoskeleton to drive the 
leading edge of the cell forward and to recruit actin-associated proteins and metallo-
proteases necessary for the degradation of the extracellular matrix (ECM). 
miR-200/ZEB1 axis and the extracellular matrix 
MicroRNAs are small non-coding RNAs that bind to the 3’ untranslated region 
(3’UTR) of genes, thereby regulating their expression by targeting them for 
degradation or repression of translation [10]. The miR-200 family consists of five 
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family members, 200a/b/c, 141 and 429, located on two different genomic loci: 200b-
200a-429 (chromosome 1) and 141-200c (chromosome 12). MiR-200 has been 
shown to be a master regulator of EMT, partially through the double-negative 
feedback loop with the transcriptional repressors ZEB1/2, maintaining the epithelial 
phenotype [11-15]. Previous studies have shown that loss of miR-200 is necessary 
and sufficient to drive EMT [16], yet the detailed mechanism on how the 
mesenchymal phenotype is maintained are not fully understood.  
Recent studies have been focused on the importance of the ECM in 
mediating tumor cell activation, indicating that metastasis is driven by a combination 
of cell-intrinsic and cell-extrinsic changes. The miR-200/ZEB1 axis is known to 
regulate both, cell-intrinsic and cell-extrinsic changes, by modulating EMT markers 
and specific ECM components. Over the past years studies have shown that the 
ECM undergoes dramatic changes during tumor progression, affecting the tension in 
the surrounding microenvironment (e.g. through collagen fibers) as well as 
differential expression patterns of microRNAs and integrins, which further alter 
downstream signaling pathways [7, 17, 18]. Proteomic profiling of cell lines derived 
from our murine model showed differential expression of cell adhesion and ECM 
proteins in metastatic vs. non-metastatic cell lines [19].  
Tumor cell-ECM interactions through integrins 
The interaction of cells with the ECM is mainly mediated through integrins, 
heterodimeric receptors leading to the activation of downstream intracellular 
signaling pathways. There are 18 α and 8 β subunits whose pairs are unique to their 
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ligands. Structurally they are transmembrane glycoproteins with a large N-terminal 
extracellular domain, a single transmembrane domain and a short non-catalytic C-
terminal intracellular tail. Many of the integrin subunits have been implicated to play 
an important role in cancer progression due to their role in migration and invasion in 
which they mediate the adhesion to the ECM and as result are able to regulate 
various intracellular signaling pathways. It is known that Integrins re-localize to 
adhesive structures causing alterations in their binding ability to the ECM. Once they 
bind to the ECM, cluster formation of the integrins is initiated, allowing for the 
recruitment of adaptor molecules, connecting the integrins with the actin 
cytoskeleton, kinases and other transmembrane growth-factor receptors. Integrins 
function through a bi-directional signaling: outside-in and inside-out. For the inside-
out signaling, intracellular ligands (e.g. talins) cause the separation of the 
cytoplasmic tails which in turn promotes the binding of ECM ligands to the 
extracellular domain. The outside-in signaling is initiated by the binding of ECM 
ligands to the N-terminus, causing the separation of the cytoplasmic domains which 
allows for the interaction with adaptor molecules. It has been shown that increased 
integrin activation is necessary for cancer cell migration and metastases, even 
suggesting that cancer cells might use specific integrin-ligand combinations at 
distant sites to allow for colonization and to receive mitogenic signals. Integrin 
signaling, especially through β1, involves the activation of the focal adhesion kinase 
(FAK), leading to further downstream recruitment of adaptor molecules such as 
paxillin and p130cas [20, 21]. Blocking antibodies and a non-RGD (Arginyl-glycyl-
aspartic acid ) based peptide inhibitor have been used to inhibit Integrin β1 which 
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suppressed in vitro and in vivo growth of human breast cancer and the monoclonal 
antibody volociximab against α5β1 has shown good efficacy and tolerance in Phase 
I studies. Furthermore, the blocking antibody has been shown to increase apoptosis 
in 3D breast cancer models and sensitized cancer cells to irradiation in breast 
cancer xenografts [20, 22, 23].  
Focal adhesions and FAK/Src signaling 
Focal adhesions are considered clusters of transmembrane receptors of 
integrin and cytoplasmic proteins such as FAK and other adaptor molecules involved 
in downstream signaling [24]. FAK is a signaling kinase and adaptor scaffold protein 
with an auto-phosphorylation site at tyrosine 397 [25]. Upon FAK activation, its 
substrate Src is recruited, leading to further phosphorylation of the tyrosine residues 
576/577, 861 and 925. Multiple studies have shown that activation of FAK promotes 
cell survival and motility. Furthermore, many cancers have increased FAK protein 
expression, which can lead to the formation of invasive structures such as 
podosomes and invadopodia, necessary for metastases [20, 25]. It has been shown 
that FAK is phosphorylated and re-localized to sites of focal adhesions in stiffer 
matrices, which are found upon the ECM remodeling occurring during tumor 
progression [8, 18]. Furthermore, FAK inhibition using siRNA has been 
demonstrated to increase cell-cell adhesion, an epithelial characteristic, through E-
cadherin modulation and to reduce cell invasion [21]. 
FAK and many of the adaptor molecules involved in focal adhesion signaling 
are known Src substrates. Src is one of the 11 Src-family kinase members, which 
contains an auto-phosphorylation site in the activation loop. In addition to the 
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positive regulatory site at residue Y416 (auto-phosphorylation site) it also has a 
negative regulatory site at residue Y527. The tyrosine kinase Src is an oncogene 
that is overexpressed in many cancer types and known to be involved in multiple 
cellular processes, such as proliferation, cell morphology, migration, invasion and 
adhesion. It is negatively regulated by the C-terminal Src kinase (CSK) which 
phosphorylates Src at residue Y527 to inactivate Src [26]. Furthermore, Src is 
regulated by protein tyrosine phosphatases which de-phosphorylate Src at its 
negative regulatory site. The tyrosine kinase acts as signal transducer from cell 
surface receptors (e.g. integrins) through phosphorylation of tyrosine residues on 
substrates such as FAK, Cas and paxillin. Src inhibition has been shown to 
decrease migration in vitro, tumor growth and invasion in vivo in NSCLC using 
murine xenograft models [27, 28]. Furthermore, inhibition of Src using the ATP 
binding competitive inhibitor Dasatinib decreased the development of liver 
metastases in a murine model of pancreatic carcinoma and caused a decrease in 
cell adhesion, migration and invasion in colon cancer cell lines. In thyroid cancer cell 
lines, Dasatinib was shown to have a cytostatic activity both in vitro and in vivo 
causing cell cycle arrest and an increase in senescence [29]. Yet, Dasatinib has only 
been used on patients with advanced disease and therefore not been proven 
successful in clinical trials. In addition to Dasatinib, the more specific Src inhibitor 
Saracatinib (AZD0530) has been used in multiple studies resulting in a growth 
inhibition in several cancer cell lines and reduced migration and invasion [30]. 
Combination treatment of Saracatinib with an EGFR/HER2 drug in breast cancer 
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has shown to cause cell cycle arrest and as result suppressed the formation of brain 
metastases which are normally promoted by Src [31].  
The formation of the FAK/Src complex at sites of focal adhesions is 
necessary in mediating cell-matrix contacts and cytoskeletal reorganization, mostly 
through regulating the phosphorylation status of the cytoskeletal protein cortactin, 
which is involved in cell adhesion, migration and invasion [25, 32]. The focal 
adhesion complex formation is facilitated by adaptor molecules such as CRKL, 
linking the cell-matrix interactions to intracellular signaling activation [33]. 
CRKL  
CRKL, an integrin adaptor molecule, belongs to the family of CRK proteins, 
known to control transcription and the cytoskeleton through downstream signaling 
cascades. They are activated through extracellular and intracellular stimuli, such as 
growth factors, cytokines and the tyrosine kinase Bcr-Abl, respectively. CRKL has 
been implicated to play a role in proliferation, adhesion, survival, migration and 
invasion [34, 35].  It has been found to be overexpressed in many cancer types, 
including lung, breast, skin, ovarian and colon cancer, primarily leading to enhanced 
adhesion to fibronectin, an ECM protein [33, 36-38]. Furthermore, the 
phosphorylation status of CRKL is used as a prognostic factor for CML survival [39]. 
It is known to directly interact with paxillin and p130Cas and translocates to focal 
adhesions upon Src activation [40]. 
8 
 
This study is focused on understanding how the miR-200/ZEB1 axis controls 
the matrix-dependent tumor cell activation by modulating cell-cell and cell-matrix 
interactions and cytoskeletal changes, necessary to drive the invasive phenotype.  
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Chapter 2 
Materials and 
Methods 
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Animal studies.  
All animal experiments were approved by the institutional animal care and 
use committee (IACUC) at the University of Texas M.D. Anderson Cancer Center. 
Wild type male and female mice from the 129/sv strain with a minimum age of 2 
months were used for the mice experiments. 0.5 -1 x 106 cells were subcutaneously 
injected in the flank in a volume of 100 μl in serum free RPMI. The animals received 
intraperitoneal injections 5 days a week with dasatinib (purchased from 
Selleckchem) at a dose of 10 mg/kg or 20 mg/kg in a volume of 50 μl or the vehicle 
DMSO. The animals were monitored for tumor burden and sacrificed once the tumor 
size exceeded 15 mm or euthanized due to tumor ulcerations. Mice were examined 
for metastasis and tissues for the subcutaneous tumor, lungs and any organs with 
visible metastasis were collected. The results are represented as mean ± standard 
deviation and student’s t-test was performed for statistical significance. 
Cell culture.  
Cell lines derived from the mutant Kras and p53 lung adenocarcinoma mouse 
model (previously published [16]) and human lung cancer cells H157 were cultured 
in RPMI1640 with 10 % fetal bovine serum (FBS) (Table 1). HEK 293T cells were 
cultured in DMEM with 10 % fetal bovine serum (FBS).  
Cell line Species 
393LN murine 
412P murine 
393P murine 
307P murine 
531P1 murine 
531LN2 murine 
531LN3 murine 
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344LN murine 
531LN1 murine 
344P murine 
344SQ murine 
    
344SQ_200 murine 
393P_vec murine 
393P_ZEB1 murine 
393_ZEB1_vec murine 
393P_ZEB1_200 murine 
    
H157 human 
H157 pTRIPZ human 
H157 200ab human 
Table 1. Cell lines used in the study 
Inhibitors and blocking antibodies.  
The inhibitors dasatinib, AZD0530 and imatinib were a kind gift from Dr. Faye 
Johnson (MD Anderson). TGF-β was purchased from Cell Signaling (#8915LF). FAK 
inhibitor 14 (Y15) was purchased from Santa Cruz (sc-203950). All blocking 
antibodies and Ig controls were purchased from BD Biosciences and used at a final 
concentration of 8 μg/ml: Itgβ1 (BD 555002), Itgβ3 (BD 553343), IgM (BD 553957), 
IgG (553950).  
Generation of pLenti6.3 Src dominant active (DA) and dominant negative (DN) 
constructs. 
 Src DA Y527F and Src DN K295R plasmids were purchased from Addgene 
(Plasmid 17675 and 17678). Following the Gateway® Technology cloning manual 
PCR primers were designed adding attB sites to each of the Src DNA sequences 
(Src attB F: GGGGACAACTTTGTACAAAAAAGTTGGCATGGGGAGCAGCAAGA 
GC, Src attB R: GGGGACAACTTTGTACAAGAAAGTTGGGCTATAGGTTCTCTCC 
12 
 
AGG). The obtained PCR products were further cloned into a pDONR221 vector 
using a BP reaction (Invitrogen 56481) and the resulting plasmids cloned into the 
Destination vector pLenti6.3 EF (kindly provided by Dr. Kenneth Scott, Baylor 
College of Medicine) using a LR reaction (Invitrogen 56484). The final plasmids were 
confirmed using Sanger sequencing and used for lentiviral infection. 
Lentivirus transfection.  
Lentiviral-based Itgβ1 shRNA were purchased from Thermo Scientific 
(mouse: TRCN0000066643, TRCN0000066644, TRCN0000066645, 
TRCN0000066646, TRCN0000066647 (also targets human Itgβ1), human: 
TRCN0000029645, TRCN0000029648). Lentiviral-based CRKL shRNA were 
purchased from Thermo Scientific (mouse: TRCN0000097199, TRCN0000097200, 
TRCN0000097202, TRCN0000097203). Murine Csk cDNA was purchased from 
Origene (MC203625) and cloned into the pTRIPZ-GFP vector. 293T cells were 
seeded one day prior to transfection. 2 μg DNA construct, 1.5 μg psPAX2 (gag-Pro-
Pol, for packaging) and 0.5 μg pMD2.G (envelope plasmid) were mixed and added 
to Opti-MEM® (GIBCO). PLUS™ reagent (Invitrogen) was added to the mixture and 
incubated for 5 minutes at room temperature. After addition of Lipofectamine® LTX 
(Invitrogen), the mixture was incubated for 30 minutes at room temperature and 
added to the cells. 8-12 hours post-transfection, the transfection mixture was 
replaced with fresh DMEM. Virus was collected 3 times every 12 hours after a 24 
hour recovery period and stored on ice at 4 °C. The virus was filtered using a 0.45 
μm syringe filter and polybrene (8 μg/ml, Millipore) was added for efficient infection 
and incubated for 10 minutes at room temperature. The target cells (344SQ, 
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393P_ZEB1 and H157) were infected 2 times with the virus (with an 8 hour time 
period in between infections). The virus was replaced with fresh RPMI 12 hours past 
the 2nd transfection and after a 24 hour recovery period antibiotic selection was 
started. 
siRNA transfection.  
The human CRKL siRNA SMARTpool was purchased from Dharmacon (L-
012023-00-0005) and used at a final concentration of 25 nM. One day before 
transfection, cells were plated in 6 well plates. The siRNA and DharmaFECT I 
(Dharmacon) were separately diluted in serum-free RPMI and incubated for 5 
minutes at room temperature. The diluted siRNA was added to the DharmaFECT 
mix and incubated for 20 minutes at room temperature before adding it to the cells. 
RNA and lysates were collected 48 hours post transfection. 
 Migration and Invasion Assay.  
Cells were seeded at a density of 5 x 104 per well in serum-free media in a 
24-well Transwell or Matrigel plate (BD Biosciences, pore size 8 μm). RPMI with 
10 % FBS was placed in the lower chamber as a chemoattractant and cells were 
allowed to migrate for 6 hours (H157 cells) or 16 hours (murine cells) at 37 °C at 5 % 
CO2. The migrated/invaded cells were stained with 0.1 % crystal violet and non-
migrated/invaded cells in the upper chamber removed using a cotton swab. Five 
microscopic fields at a 4x magnification were captured from each well and 
migrated/invaded cells counted.  The results are represented as mean ± standard 
deviation and student’s t-test was performed for statistical significance. The graphs 
in each figure represent one experiment. Each assay was performed in triplicates. 
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Cell Adhesion Assay.  
Wells of a 24 well plate were coated with a thin layer of either Fibronectin 
(10 μg/ml, Sigma F1141), Matrigel, Matrigel/Collagen type I (final concentration 
1.5 mg/ml) or Collagen type I (final concentration 1.5 mg/ml, Corning). Cells were 
pre-treated with Y15 (5 μM) for 24 hours before 50,000 cells/well were plated. After 
the incubation time, each well was washed twice with PBS to remove unattached 
cells, fixed for 10 minutes at room temperature with 10 % formalin, washed with PBS 
and stained using 0.1 % Crystal Violet/PBS. Images are representatives of the 
triplicates performed for each condition. For the washout experiment, pre-treated 
cells were washed and added to the wells without Y15. Quantification of cell 
adhesion was measured by the absorbance at 595 nm after dissolving the crystal 
violet stained cells in 10 % acetic acid for 20 min. 
Quantitative Real-Time PCR.  
RNA was isolated using TRIzol® Reagent (Invitrogen) according to the 
manufacturer’s protocol and reverse transcribed into cDNA using qScript™ Reagent 
(Quanta Biosciences) or iScript™ (Bio-Rad). mRNA levels were measured using 
SYBR® Green-based detection (Applied Biosystems) on an ABI 7500 Fast Real-
Time PCR System (Applied Biosystems). The primers were designed using the NIH 
primer design tool. For each gene a dissociation curve was generated and the 
results of each sample normalized to the ribosomal protein L32, which serves as 
internal control. All measurements were performed in triplicate and expressed as 
mean ± standard deviation. Student’s t-test was performed for statistical 
significance. Analysis of the microRNA levels was performed following the TaqMan 
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microRNA protocol (Applied Biosystems) and results were normalized to the control 
miR-16. All TaqMan probes were purchased from Life Technologies (miR-200a 
Assay ID: 000502, miR-200b Assay ID: 001800, miR-200c Assay ID: 000505, miR-
141 Assay ID: 000463, miR-429 Assay ID: 001077, miR-16 Assay ID: 000391). 
Primer sequences are listed in (Table 2).  
qPCR primer 5' to 3' 
 ms L32: F GGAGAAGGTTCAAGGGCCAG 
ms L32: R TGCTCCCATAACCGATGTTG 
ms Zeb1: F ATGCTCTGAACGCGCAGC 
ms Zeb1: R AATCGGCGATCTTTGAGAGCT 
ms CDH1: F CCATCTCAAGCTCGCGGATA 
ms CDH1: R TCCAACGTGGTCACCTGGT 
ms CDH2: F TCCAGAGGGATCAAAGCCTGGGAC 
ms CDH2: R CCGCATCAATGGCAGTGACCGT 
ms Vim: F TCCAAGCCTGACCTCACTGC 
ms Vim: R TTCATACTGCTGGCGCACAT 
ms Crb3: F CGGACCCTTTCACAAATAGCA 
ms Crb3: R CGTTGGACTCATCACCTGGG 
ms Itgb1: F CTACTTCTGCACGATGTGATGAT 
ms Itgb1: R TTGGCTGGCAACCCTTCTTT 
ms Itgb2: F CAGGAATGCACCAAGTACAAAGT 
ms Itgb2: R CCTGGTCCAGTGAAGTTCAGC 
ms Itgb3: F CCACACGAGGCGTGAACTC 
ms Itgb3: R CTTCAGGTTACATCGGGGTGA 
ms Itgb4: F AGAGCTGTACCGAGTGCATC 
ms Itgb4: R TGGTGTCGATCTGGGTGTTCT 
ms Itgb6: F GAAAACCCTGTCTCCCGCATA 
ms Itgb6: R CGCTGAGAGGCTTATTTTGAAGG 
ms Itgb7: F ACCTGAGCTACTCAATGAAGGA 
ms Itgb7: R CACCGTTTTGTCCACGAAGG 
ms CSK: F AAGGTGGAGCACTACCGCATCA 
ms CSK: R AGAGTCCATCGGCATCTGTGGT 
ms Src: F GAGTCACGGACAGAGACTGA 
ms Src: R GACATCCACCTTCCTCGTGT 
ms CRK: F CTAATGCCTACGACAAGACAGCC 
ms CRK: R TGGGAAGTGACCTCGTTTGCCA 
ms CRKL: F CCTGGACACTACCACCTTAATCG 
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ms CRKL: R TCTTCTGCTGTAGGTAAGTTGGG 
ms PINCH1: F GGGTTTGTCAAGAATGCTGGCAG 
ms PINCH1: R GCACAGTTGAAGTGGTCTGGATG 
ms NEDD9: F TCTAAGCAAGGACCAGCCACCA 
ms NEDD9: R CTCCTTCTGCTGTCGCTCAAAC 
ms ILK: F GTGCTGAAGGTTCGTGACTGGA 
ms ILK: R TCCAGTGTGTGATGAGGGTTGG 
    
hs L32: F CCTTGTGAAGCCCAAGATCG 
hs L32: R TGCCGGATGAACTTCTTGGT 
hs Zeb1: F GGCATACACCTACTCAACTACGG 
hs Zeb1: R TGGGCGGTGTAGAATCAGAGTC 
hs Itgb1: F GGATTCTCCAGAAGGTGGTTTCG 
hs Itgb1: R TGCCACCAAGTTTCCCATCTCC 
hs_CRKL Ori: F ATCCACTACCTGGACACCACCA 
hs_CRKL Ori: R CCAGGTTATCTTCTGCTGTAGGC              
Table 2. Primer sequences used for qPCR analysis 
 
Western Blot Analysis.  
Cell lysates were prepared according to the RIPA buffer protocol (CS 9806). 
Samples were separated using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred onto Nitrocellulose or polyvinylidene difluoride 
(PVDF, for p-CRKL antibody only) membranes. The membranes were blocked using 
5 % nonfat dry milk and incubated in primary antibody overnight at 4 °C (see Table 3 
 for antibody list). 
Protein Company Catalog Number 
Cortactin MilliPore 05-180 
Crkl MilliPore 05-414 
Crkl pY207 Cell Signaling 3181 
Csk BD Pharmingen 610080 
Cttn pY421 Invitrogen 44854 
Cttn pY421 Abcam 47768 
E-Cadherin BD Pharmingen 610182 
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FAK Invitrogen AHO0502 
FAK pY397 Invitrogen 44624G 
FAK pY576/577 Cell Signaling 3281 
FAK pY861 Invitrogen 44-626G 
FAK pY925 Cell Signaling 3284 
GFP Santa Cruz 9996 
Integrin β1 Cell Signaling 4706 
N-cadherin BD Pharmingen 610921 
p130Cas Upstate 06-500 
p130Cas pY410 Cell Signaling 4011 
Paxillin BD Pharmingen 610620 
Paxillin Abcam 2264 
Paxillin pY118 Abcam 4833 
Src Cell Signaling 2108s 
Src pY416 Cell Signaling 2101L 
Src pY418 MilliPore 569373 
Src pY527 Cell Signaling 2105 
Vimentin Cell Signaling 3932S 
Zeb1 Santa Cruz 25388 
      
Table 3. List of antibodies used for Western Blot analysis 
3D culture.  
Cells were grown in 8-well chamber slides coated with Matrigel (BD 356231) 
or Matrigel/Collagen (BD 354249, at the indicated Collagen concentration), as 
previously described. [16] The media (RPMI with 10 % FBS and 2 % Matrigel) was 
replaced every 2-3 days and the morphology of the cells monitored using a light 
microscope. Size of the structures and invasion were scored at the end of the 
experiment, with structures being counted invasion-positive if ≥ 1 protrusions were 
present. Immunofluorescent staining of the 3D cultures was performed as previously 
described [16]. Protein isolation from 3D assays was performed using PBS-EDTA as 
previously described [41]. In brief, each well was washed with ice-cold PBS before 
adding PBS-EDTA. The Matrigel or Matrigel/Collagen layer was detached from the 
glass slide, transferred into a falcon tube and briefly vortex to ensure disruption of 
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the layer. The mixture was left on ice for 25 minutes until a pellet formed and 
centrifuged at 115 g for 5 minutes. The pellet was washed twice with PBS-EDTA and 
spun at 4,000 rpm for 2 minutes before the cells were lysed with RIPA buffer for 
30 minutes on ice. The lysate was cleared by centrifugation and protein estimation 
performed. For dissolving the Matrigel/Collagen layer, a Collagenase treatment was 
performed after the initial wash. Each well was incubated with Collagenase Type I 
(1,000 U/ml, Calbiochem #234153) for 30 minutes at 37 °C.   
Immunohistochemistry.  
All tissues were formalin fixed and paraffin embedded. The paraffin 
embedded tissue sections were deparaffinized in xylene twice for 5 minutes at room 
temperature followed by hydration of the samples in graded ethanol (twice 100 %, 
twice 95 %, 80 %) for 5 minutes each at room temperature. Antigen retrieval was 
performed in citrate buffer (DAKO #S1699) for 25 minutes at 95 °C and allowed to 
cool for 20 minutes. Endogenous peroxidase activity was blocked by incubating the 
slides in 3 % H2O2 diluted in methanol for 5 minutes. Non-specific protein-protein 
interactions were blocked using serum-free protein block (DAKO #X0909) for a 
minimum of 1 hour at room temperature. The primary antibody p-Src Y418 
(MP569373) was added to the slides at a dilution of 1:50 overnight at 4 °C. For the 
negative controls, goat serum was added. After washing with TBST, slides were 
treated with a secondary biotinylated antibody (1:300, DAKO #0353) for 30 minutes 
at room temperature followed by incubation with peroxidase-conjugated streptavidin 
(1:100, DAKO #P0397) for 30 minutes. Visualization of the antibody staining was 
performed by adding Chromagen substrate diluted in DAB buffer (DAKO #K3468) 
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followed by a counterstain in Hematoxylin for 6 minutes and Scott’s Bluing Reagent. 
Slides were dehydrated in graded ethanol for one minute each (80 %, 95 %, 100 %) 
followed by incubation in xylene twice for 10 minutes each.  
Immunofluorescence.  
Acid-washed 18 mm coverslips were coated with either 50 μg/ml poly-L-lysine 
or fibronectin (10 μg/ml) before 20,000 cells were plated and grown overnight. Cells 
were fixed with 4 % paraformaldehyde/PBS for 20 minutes at 37 °C and washed 
three times with PBS. Permeabilization was performed using 0.1 % Triton X-100 for 
10 minutes at room temperature followed by three PBS washes. The coverslips were 
blocked for a minimum of 1 hour at room temperature with 5 % goat serum/PBS 
before the primary antibodies were added overnight at 4 °C (Cortactin Millipore 05-
180, 1:1000; p-Src Y418, Millipore 569373, 1:50; p-FAK Y861 Invitrogen 44626, 1:50; 
Paxillin BD610620, 1:100). After three washes with PBS, the coverslips were 
incubated with secondary antibodies labelled with Alexa Fluor® 488 or 546 (Life 
Technologies) for 2 hours at room temperature. Staining of F-actin was performed 
using Alexa Fluor® 546 Phalloidin (Life Technologies). After the secondary antibody 
incubation the coverslips were mounted onto microscope slides using a DAPI 
containing mounting solution for the nuclear stain.  
Luciferase Reporter Assay.  
The three prime untranslated regions (3’-UTRs) were amplified by PCR from 
genomic DNA and mutants generated using a QuikChange® II XL site-directed 
mutagenesis kit (Stratagene), which were further cloned into the hRL vector. One 
day before transfection, 3 x 104 cells were seeded in 24 well plates and co-
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transfected with 50 ng pGL3 control vector and 500 ng hRL constructs. Pre-miRs 
were added at a final concentration of 30 nM (Ambion). After 48 hours Luciferase 
activity was measured following the protocol for the Dual-Luciferase® Reporter 
Assay (Promega).  
Cytosol/Particulate Separation. 
 The separation of cytosol and particulate was performed using a 
cytosol/particulate rapid separation kit purchased from BioVision (#K267-50). The 
workflow is depicted in Fig. 1. 
 
 
 
 
Fig. 1 Workflow of cytosol/particulate separation. Using this 
separation method the cytosol and particulate fractions do 
not come into contact therefore contaminations can be 
avoided. 
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Results 
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Zeb1 expression induces a functional EMT in epithelial, non-invasive tumor 
cells.  
 Our previous work with metastasis-prone tumor cells from the KP murine 
model revealed that miR-200 repression is necessary in a subset of cells at the 
tumor periphery for EMT and metastasis [16, 42]. To test whether Zeb1 expression 
in tumorigenic, but non-metastatic cells was sufficient to induce a mesenchymal and 
invasive phenotype similar to that observed in the metastasis-competent cells, stable 
transfectants were generated with constitutive Zeb1 expression. Constitutive Zeb1 
expression in the epithelial 393P cells from the KP model produced a dramatic 
morphologic change, with cells displaying a spindle-like, fibroblastic shape (Fig. 2A 
& B). This change was partially reversed by re-expression of miR-200, as seen in 
the lower panel of (Fig. 2A). F-actin staining demonstrated that the mesenchymal, 
invasive 344SQ and 393P_ZEB1 cells display cell protrusions, long actin stress 
fibers and enhanced cell matrix contact, which were lost upon miR-200 expression 
(Fig. 2B). The morphologic change observed with Zeb1 was concordant with an 
EMT, as shown by the mRNA and protein levels of epithelial and mesenchymal 
markers (Fig. 3A) and decreases in the miR-200 family (Fig. 3B). As a functional 
consequence, Transwell migration and invasion were enhanced in the previously 
non-invasive 393P cells, and suppressed upon miR-200 re-expression (Fig. 3C). 
Similar results were obtained with a doxycycline-inducible system to express miR-
200a and/or b in the human H157 lung cancer cell line, producing an MET with 
morphologic reorganization into tight epithelial clusters (Fig. 4A), suppression of 
mesenchymal and re-expression of epithelial protein markers (Fig. 4B), with the 
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Fig. 2 Zeb1 expression induces EMT. (A) 
Zeb1 expression causes a morphology 
change (middle panel) and is reversed 
upon re-expression of miR-200 (lower 
panel). Cells were stained with Integrin α6 
(red), ZO-1 (green) and DAPI. (B) Cells 
grown on agarose and stained with 
phalloidin (red), DAPI and cortactin 
(green, lower panels). 
24 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Zeb1 expression induces EMT/miR-200 repression in previously 
non-invasive cells. (A) Quantitative RT-PCR (left) and Western Blot 
(right) analysis of EMT markers in the indicated cell lines. (B) Taqman 
RT-PCR for the miR-200 family members in the indicated cell lines. (C) 
In vitro migration and invasion assay for the 393P cell line panel.           
* p < 0.004, ** p < 0.001 
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Fig. 4 Loss of miR-200 in human H157 cells 
causes an MET. (A) Induction of miR-200a and 
b in H157 causes a morphology change. (B) 
Western Blot analysis of EMT markers in H157 
+/- miR-200a and/or b. (C) In vitro migration 
and invasion assay for the inducible H157 cells. 
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most pronounced effect seen upon combined miR-200a and b expression. The 
induction of MET in H157 cells upon miR-200 induction significantly suppressed the 
migratory and invasive ability of the cells in Transwell assays (Fig. 4C). 
 
miR-200 repression alters cell-cell and cell-matrix interactions.  
We utilized a well-established 3D culture assay to study the importance of the 
ECM in regulating tumor cell behavior in coordination with Zeb1/miR-200 expression 
changes [41]. To model the extracellular matrix composition found in tumors, cells 
were grown on a Matrigel matrix or a mixture of different Matrigel/collagen type I 
concentrations and then stained for markers to reveal the differential 3D 
organization. Control cells grew as rounded, non-invasive colonies in all conditions, 
but upon Zeb1 expression displayed a progressively invasive response upon growth 
in collagen type I, dependent upon the collagen concentration (Fig. 5A, middle row, 
and Fig. 5B). At the highest collagen concentration, ~70% of the colonies were 
invasive. Upon re-expression of miR-200 the cells displayed a more organized 
epithelial acinar structure in Matrigel culture, with pronounced cortical actin staining, 
and suppression of the collagen-induced invasion (Fig. 5A, bottom row). These 
results suggest that miR-200 repression enhances the response of the cells to 
external stimuli from the ECM, producing a highly invasive phenotype. 
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Fig. 5 miR-200 repression primes cells to external stimuli and causes alterations in 
cell-cell & cell-matrix interactions. (A) Morphology of spheres grown in a Matrigel 
matrix (left two columns) and stained with Integrin α6 (red), ZO-1 (green) and DAPI; 
or grown in a mixture of Matrigel and collagen I at the indicated concentrations. (B) 
Quantification of the spheres grown in Matrigel (MG) and Matrigel/collagen I at day 
7. For each condition 30 structures were measured in size and 75 structures scored 
for invasiveness. 
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Integrin β1 is necessary for the invasion of murine mesenchymal cell lines.  
 Integrins are important sensors of the cellular environment, transducing 
changes in the surrounding ECM to drive intracellular signaling. Based upon the 
altered responsiveness of tumor cells to collagen I in the matrix upon loss of miR-
200, we screened for changes in the expression or functionality of integrin subunits 
induced by EMT. Screening of multiple integrin β subunits revealed that Itgβ1 is 
highly expressed in the mesenchymal 393P_ZEB1 cells. Additionally, Itgβ1 was up-
regulated in the 2D vs. 3D cultures of 344SQ, paralleling the normal changes in miR-
200 expression upon 3D growth (Fig. 6A). Western Blot analysis of the murine cell 
panel showed expression of Itgβ1 in epithelial and mesenchymal cell lines, with only 
slightly higher expression in the mesenchymal cells (Fig. 7A). We next investigated 
the functional effect of an Itgβ1-blocking antibody on tumor cell invasion in 3D 
cultures. The antibody significantly decreased the invasive ability of 393P_ZEB1 
cells when grown in Matrigel/collagen I (Fig. 7B), as compared to an Itgβ3-blocking 
antibody that produced no effect (Fig. 6B). In addition, combined treatment of Itgβ1 
and Itgβ3-blocking antibodies showed a dominant effect of Itgβ1 over Itgβ3, as 
addition of α-Itgβ1 at day 4 when cells were beginning to form invasive structures, 
still blocked the invasive phenotype. To further confirm the importance of Itgβ1 in 
mediating invasion, we used an shRNA-based knockdown approach to deplete 
highly invasive 393P_ZEB1 cells of Itgβ1, as confirmed by mRNA and protein levels 
(Fig. 8A). Knockdown of Itgβ1 caused a significant reduction in Transwell invasion 
for all of the tested shRNAs, blunted migration for three of the four tested shRNAs 
(Fig. 8B), and produced a shift to a more epithelial phenotype (Fig. 8C). Strikingly,  
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Fig. 6 Integrin β1 is required for mesenchymal cell invasion. (A) 
Quantitative RT-PCR analysis of Integrin β subunits in 393P_ZEB1 vs vec 
cells (top panel) and in 344SQ grown in 2D vs 3D Matrigel (lower panel) 
(B) 393P_ZEB1 cells grown in 1.75 mg/ml Matrigel/collagen I and treated 
with an Integrin β3-blocking antibody alone, in combination with an Integrin 
β1-blocking antibody (added at the days indicated) or IgG control for 7 
days.  
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Fig. 7 Integrin β1 inhibition blocks 3D invasion in 
murine mesenchymal cell lines. (A) Integrin β1 
expression in the murine cell line panel. (B) 
393P_ZEB1 cells grown in 1.75 mg/ml 
Matrigel/collagen I and treated with an ITGβ1-
blocking antibody or IgM control for 7 days. 
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Fig. 8 Integrin β1 knockdown blocks 2D invasion in murine mesenchymal cell 
lines. (A) Quantitative RT-PCR and Western Blot analysis of 393P_ZEB1 cells 
after ITGβ1-shRNA knockdown. (B) In vitro migration and invasion assay for the 
Itgβ1 shRNA cells. * p < 0.02, ** p < 0.002, *** p ≤ 0.001 (C) Morphology of 
393P_ZEB1 cells after Itgβ1 knockdown. 
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the Itgβ1 shRNA inhibited 3D invasion in Matrigel/collagen I cultures of 393P_ZEB1 
cells to a similar degree as the Itgβ1-blocking antibody (Fig. 9A). We further 
depleted the highly metastatic 344SQ cells of Itgβ1, as confirmed by mRNA and 
protein levels (Fig. 10A). All of the tested shRNAs showed a significant reduction in 
Transwell invasion without any effect on the migration (Fig. 10B), as well as a 
morphology change to a more epithelial phenotype in shRNA 5 (Fig. 10C). In order 
to see if Itgβ1 knockdown can blunt TGFβ-induced EMT, the shRNA cells were 
grown in Matrigel in 3D and treated with TGFβ, which normally causes a hyper-
proliferative and highly invasive phenotype. Itgβ1 knockdown caused a significant 
reduction in the responsiveness to TGFβ, as quantified by sphere size and invasion 
(Fig. 10D). In addition, knockdown of Itgβ1 significantly decreased the number of 
lung metastases in vivo (Fig. 11).  Moreover, widespread metastases were found in 
the liver, kidneys, intestines, heart, rib cage and diaphragm of the control mice but 
none were observed in the mice who received tumor cells with Itgβ1 knockdown 
(Fig. 11). 
 
Integrin β1-collagen I contact is necessary for H157 cell growth and invasion.  
To confirm the effect of the Itgβ1-blocking antibody with human cells, we 
treated the mesenchymal H157 cells with α-Itgβ1 either from day 0 or day 7, when 
the cells were starting to form invasive structures. In both treatment groups, 3D 
invasion was significantly inhibited (Fig. 12A), confirming the observations with the 
murine  cells . shRNA-based  knockdown  of  Itgβ1  produced  a  partial  MET with  
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Fig. 9 Integrin β1 shRNA knockdown blocks 3D 
invasion in murine mesenchymal cell lines. (A) 
393P_ZEB1 Itgβ1 shRNA cells grown in 1.75 mg/ml 
Matrigel/collagen I at day 6. For each condition 30 
structures were measured in size and 90 structures 
scored for invasiveness. Scale bar represents 200 
μm. 
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Fig. 10 Integrin β1 knockdown blocks 2D invasion and 3D responsiveness to 
TGFβ in murine mesenchymal cell lines. (A) Quantitative RT-PCR and Western 
Blot analysis of 344SQ cells after ITGβ1-shRNA knockdown. (B) In vitro 
migration and invasion assay for the Itgβ1 shRNA cells. * p < 0.015, ** p = 
0.0002 (C) Morphology of 344SQ cells after Itgβ1 knockdown. (D) 344SQ Itgβ1 
shRNA cells grown in Matrigel at day 11. TGFβ treatment (1 ng/ml) was started 
at day 6. For each condition 30 structures were measured in size and 90 
structures scored for invasiveness. Scale bar represents 200 μm. 
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Fig. 11 Integrin β1 shRNA knockdown reduces metastases in vivo. (A) 
Mice injected with 344SQ Itgβ1 shRNA showed a significant reduction in 
the number of lung metastases. (B) Control mice showed distant 
metastases (e.g. intestines, heart), which were absent in the shRNA 
mice. 
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Fig. 12 Integrin β1 inhibition blocks 3D invasion 
in human mesenchymal cell lines. (A) H157 cells 
grown in 1. 5 mg/ml Matrigel/collagen I and 
treated with an ITGβ1-blocking antibody from 
day 0 or day 7 or IgM control. 90 structures were 
scored for invasiveness. 
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decreased Zeb1 and  N-cadherin  levels  and   a decreased downstream activation 
of the FAK/Src pathway (Fig. 13A & B). This effect was also observed upon miR-
200ab induction in H157 wild-type cells (Fig. 14B), which also causes a decrease in 
the formation of invasive cell protrusions (Fig. 14A). This 3D phenotype was 
resembled in the cells treated with the Itgβ1-blocking antibody (Fig. 12A). 
Furthermore, the Itgβ1-knockdown cells had a more epithelial morphology (Fig. 14C) 
and decreased invasion in Transwell assays (Fig. 15B). In 3D Matrigel/collagen I 
cultures the control cells displayed a growth advantage versus the Itgβ1 knockdown 
cells and were significantly more invasive. Interestingly, despite normal growth in 2D 
culture the shRNA84 Itgβ1 KD cells were unable to survive in 3D culture (Fig. 15A). 
This result suggests that the Itgβ1-collagen I interaction mediates pro-
growth/survival and pro-invasive signaling. 
 
Invasion of the mesenchymal cells is dependent on FAK/Src pathway 
activation.  
 Given the observed FAK/Src pathway activation, we sought to study the 
importance of this pathway downstream of Itgβ1-matrix interactions in our murine 
cell line panel. Western Blot analysis showed significant activation of the FAK/Src 
pathway (including FAK, Src, paxillin, and cortactin) in the mesenchymal cells 
compared to the epithelial cells (Fig. 16A), along with increased phospho and total 
CRKL expression. Moreover, in the genetically manipulated 393P cells we observed 
an inverse correlation between the activation of this pathway, CRKL expression and 
the miR-200 levels (Fig. 16B). Inhibition  of  FAK with  the  reversible  inhibitor, Y15 
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Fig. 13 Integrin β1 knockdown in human H157 cells. (A) 
Quantitative RT-PCR and (B) Western Blot analysis of H157 
cells after Itgβ1-shRNA knockdown shows a partial MET. 
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Fig. 14 MiR-200 re-expression and Integrin β1 knockdown in H157 
cells cause an MET. (A) H157 cells grown in 3D culture 
(Matrigel/collagen mixture) for 11 days. (B) Western Blot analysis of 
the FAK/Src pathway of H157 cells after induction of miR-200. (C) 
H157 Itgβ1 knockdown cells stained for F-actin with Phalloidin and 
DAPI for the nucleus. Scale bar is 200 μm. 
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Fig. 15 Integrin β1-collagen I contact is necessary for 
H157 survival. (A) In vitro migration and assay for the 
Itgβ1 shRNA cells. * p < 0.001, ** p < 0.0001 (B) ITGβ1-
knockdown cells grown on Matrigel/collagen I for 13 days 
and analyzed for sphere size and invasiveness. Cells for 
sh84 are pseudo colored and not included in graphical 
analysis due to phenotype. Scale bar is 200 μm.              
* p ≤ 0.0001  
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Fig. 16 The FAK/Src pathway is activated 
in mesenchymal cell lines. (A) Western 
Blot analysis shows increased 
FAK/Src/Cortactin pathway activation in 
the mesenchymal cells lines of the 
murine cell line panel and in cell lines 
stably expressing Zeb1 (B). 
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(Fig. 17A), significantly decreased 2D migration and invasion (Fig. 17B), and 
disassembly of pre-formed invasive cell protrusions in 3D 393P_ZEB1 cultures 
within 72 hrs (Fig. 17C). This disassembly was due to decreased cell adhesion as 
seen in a cell adhesion assay in which pre-treated cells were grown on different 
matrices (Fig. 18A). Cells that received continuous Y15 treatment showed a 
decreased ability to adhere, but removal of the inhibitor at the time of plating 
revealed that this effect was reversible (rather than a consequence of cell death). 
Taken together these results reveal that Itgβ1-mediated invasion is dependent upon 
FAK signaling. 
 
Mesenchymal cell invasion is mediated through activated Src signaling.  
The tyrosine kinase Src is known to interact with activated FAK, producing 
additional FAK phosphorylation at the tyrosine residues Y576/577, Y861 and Y925, 
as observed upon ZEB1 expression in the 393P cells (Fig. 19A). To further study the 
importance of the FAK/Src pathway in regulating invasion, we assayed the effect of 
the Src tyrosine kinase inhibitor, dasatinib. Dasatinib treatment blocked FAK 
activation (Fig. 19A) and significantly reduced 2D migration and invasion, 
suppressing the highly invasive 393P_ZEB1 cells to the baseline control levels (Fig. 
19B). Dasatinib treatment in 3D assays blocked FAK/Src signaling (Fig. 20C), and 
inhibited the collagen I-dependent invasion of the mesenchymal 393P_ZEB1 cells 
(Fig. 20A & B). Moreover, combination treatment of dasatinib with an Itgβ3-blocking 
antibody phenocopied the combined Itgβ3/Itgβ1-blocking antibody treatment       
(Fig. 21 A and B). To rule out off targets effects of dasatinib, we used the tyrosine 
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Fig. 17 The FAK/Src pathway is activated in mesenchymal cell lines and 
required for cell invasion. (A) FAK/Src/Cortactin pathway activation in the 
mesenchymal cells lines is inhibited upon a 24 hr treatment with a FAK 
inhibitor (Y15). (B) In vitro migration and invasion assay of 393P_ZEB1 
cells treated with Y15 (5 μM). (C) FAK inhibition of 393P_ZEB1 cells in 
Matrigel/collagen I causes the disassembly of cell protrusions (day 7 
pictures). Scale bar is 200 μm.  
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Fig. 18 Treatment with the FAK inhibitor affects cell adhesion and is 
reversible. (A) 393P_ZEB1 cells pre-treated with the FAK inhibitor Y15 
(5μM) for 24 hrs before plated on the different matrices as indicated (FN: 
Fibronectin, MG: Matrigel, Coll: collagen type I). Cells were fixed and 
stained after 7 hrs post plating. 
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Fig. 19 Invasion of the mesenchymal cells is mediated through activated 
Src signaling. (A) Western Blot analysis of 393P_ZEB1 and control cells 
after dasatinib treatment for 7 hrs. (B) Dasatinib treatment inhibits the 
migratory and invasive ability of mesenchymal cells in Transwell assays. 
46 
 
  
Fig. 20 3D invasion of the mesenchymal cells is mediated through activated 
Src signaling and substrate dependent. (A) 393P_Zeb1 and control cells 
grown in 3D cultures. Invasion of 393P_Zeb1 cells in a mixture of 
Matrigel/collagen I (1.75 mg/ml) is inhibited upon dasatinib treatment (50 
nM). Images were taken at day 7 after a 3 day treatment. (B) Quantification 
of sphere size and invasiveness of cells in 3D cultures from (A). 
Represented is the average of 3 wells, each measuring 30 structures in size 
and scoring 50 structures for invasiveness. (C) Western Blot analysis of cells 
grown in 3D from (A) after dasatinib treatment. 
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Fig. 21 Dasatinib treatment mimics the Integrin β1 
phenotype in 3D assays. (A) 393P_ZEB1 cells grown on 
Matrigel/collagen and treated with Itgβ3 blocking-
antibody alone or in combination with dasatinib or an 
Itgβ1 blocking-antibody (combined treatment started day 
4). (B) Images and quantification of sphere size and 
invasion were taken at day 7. Scale bar is 200 μm. * p < 
0.007, ** p = 0.0002, *** p < 0.0001. 
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kinase inhibitor Imatinib in 3D studies, which targets the same kinases as dasatinib 
except for Src. Imatinib treatment, either started at day 0 or day 4 did not inhibit 
invasion (Fig. 22A and B). Dasatinib treatment of human H157 cells blocked Src 
pathway activation, suppressing Transwell migration and invasion (Fig. 23A & B), 
and causing the cells in 3D culture to remain as single cells or tiny clusters when 
added at day 0 (Fig. 23C). Treatment with dasatinib at later time points disrupted the 
invasive structures, mimicking the miR-200 phenotype (Fig. 23C bottom row and Fig. 
24A). We further investigated the role of the ECM by comparing cells grown in 
monolayer culture to cells grown in suspension (Fig. 24B), which showed FAK/Src 
pathway deactivation in cells grown in suspension. These results demonstrate that 
the FAK/Src pathway activation is driven by the ECM composition and required for 
the mesenchymal cell invasion.  
In addition to the pharmacological inhibition of Src we utilized a genetic 
approach by using either a dominant-active (Y527F, DA) or dominant-negative 
(K295R, DN) form of Src. The DA Src was introduced into the epithelial 393P and 
412P cells, which showed an increase in activated Src (Fig. 25A) and a slight 
morphology change in the 393P cells (Fig. 25B), yet without any functional 
phenotype (Fig. 25C). In the 412P cells, the DA Src caused a decrease in migration 
(Fig. 25C), opposite to our expectations.  The DN form of Src introduced in the 
highly invasive 344SQ, 531LN2 and 344LN cells did not inhibit Src activation as 
expected by protein levels (Fig. 25D) nor was any morphology change (Fig. 25E) 
observed, but rather led to an increase in phospho-Src levels which correlated with 
an  increase  in Transwell  migration and  invasion (Fig. 25F). Those controversial  
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Fig. 22 Invasion of the mesenchymal cells is Src dependent. (A) Invasion of 
393P_Zeb1 cells grown in a mixture of Matrigel/collagen I (1.75 mg/ml) is not 
inhibited upon treatment with Imatinib (1 μM) compared to dasatinib (50 nM) 
treatment. Images were taken at day 7. Scale bar is 200 μm. (B) Sphere size and 
invasion represent the average of 3 wells with 30 structures quantified in each.  
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Fig. 23 Invasion of the human mesenchymal cells is 
mediated through activated Src signaling. (A) Western 
Blot analysis of H157 cells treated for 24 hrs with the 
dasatinib at 25 and 50 nM. (B) In vitro migration (black 
bar) and invasion (grey bar) assay of H157 cells treated 
with dasatinib (50 nM). (C) H157 cells grown in 
Matrigel/collagen I and treated with dasatinib starting at 
day 0 (pictures represent day 9).  
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Fig. 24 Dasatinib treatment mimics the Integrin β1 and miR-
200 phenotype in 3D assays. (A) H157 wild type and 
H157_200ab grown in 3D Matrigel/collagen. Dasatinib or 
vehicle were added at day 7. Images represent day 11. Scale 
bar is 200 μm. (B) Activation of the FAK/Src pathway is 
substrate dependent as seen in comparing cells grown on a 
petridish vs. suspension cells grown on low adhesion culture 
plates for 7 days. 
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Fig. 25 Dominant active (Y527F) and dominant negative (K295R) Src. (A) Western 
Blot analysis and morphology (B) of 393P and 412P cells infected with DA Src. (C) 
Migration of 393P and 412P cells with Csk. (D) Western Blot analysis and 
morphology (E) of 344SQ, 531LN2 and 344LN cells infected with DN Src.(F) 
Migration and invasion of 531LN2 cells is increased with Csk. 
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results could be explained by a possible compensation of  other  Src- family  kinase 
(SFK) members. We therefore used another approach to inhibit the SFK members 
by infecting the cells with the SFK negative regulator Csk [26]. Infection of the highly 
invasive 393P_ZEB1 cells with Csk (with or without a GFP-tag) resulted in an 
increase in Csk mRNA and protein levels after induction with Doxycycline (Fig. 26A 
and B), yet no decrease in Src activation was observed (Fig. 26B). Alterations in Csk 
levels have been shown to affect the cytoskeleton and the ability of cells to adhere to 
fibronectin, neither of which showed an effect in the infected cells (Fig. 26C and D) 
[43]. Furthermore, growth of the Csk overexpressing cells did not show a phenotype 
in a 3D Matrigel/collagen I matrix (Fig. 26E). 
 
Src inhibition blocks TGFβ-induced EMT and in vivo metastasis.  
TGFβ is a well-known EMT inducer to which we have previously shown the 
metastasis-prone KP cells are quite sensitive [16].  We next asked if Src inhibition 
would block the TGFβ-induced EMT in 344SQ or 531LN2 cells. In addition to 
dasatinib, the more specific Src inhibitor AZD0530, blocked Src pathway activation 
even in combination treatment with TGFβ (Fig. 27A). Interestingly, combined 
treatment with AZD0530 showed a decrease of Zeb1, which was reflected in the 
cellular morphology. Cells treated with TGFβ alone showed a fibroblastic phenotype, 
whereas cells that received TGFβ and AZD0530 displayed an epithelial morphology 
(Fig. 27B). Similar to the results with the invasive 393P_ZEB1 cells, treatment with 
either Src inhibitor decreased Transwell migration and invasion of the mesenchymal  
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Fig. 26 393P_ZEB1 cells infected with Csk. (A) mRNA and (B) protein levels of 
393P_ZEB1 cells infected with Csk or GFP-Csk after induction with Dox. (C) 
393P_ZEB1 cells infected with Csk grown on gelatin and stained for F-actin and 
DAPI. (D) Quantification of adhesion of the infected cells on Fibronectin at the 
indicated time points. (E) Csk does not affect invasion of 393P_ZEB1 cells in 3D 
Matrigel/collagen I. 
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Fig. 27 Migration, invasion & TGFβ response of 344SQ 
and 531LN2 cells are blocked with Src inhibitors. (A) 
Western Blot analysis of 344SQ and 531LN2 cells treated 
with Src inhibitors and TGFβ at the indicated 
concentrations for 3 days. (B) Morphology of the 344SQ 
cells in the indicated treatment conditions. (C) The 
migratory and invasive Transwell assays upon DMSO, 
dasatinib (50 nM) or AZD0530 (3 μM) treatment. 
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344SQ and 531LN2 cells (Fig. 27C). In 3D culture, treatment of 344SQ cells with 
TGFβ   caused   the   spheres   to  hyper-proliferate   and   become  highly   invasive 
(Fig. 28A, left column), as reported [16]. Combined treatment with TGFβ and either 
of the Src inhibitors led to a significant reduction in sphere size and invasion, which 
was more pronounced with AZD0530 (Fig. 28A & B).  
The 344SQ cells are paradigmatic of the highly metastatic KP cells in our 
syngeneic murine model [16]. To assess whether dasatinib blockade of the Src 
signaling pathway could suppress metastases, we injected syngeneic mice with 
344SQ cells and dosed them with 10 or 20 mg/kg dasatinib 5 days/week. The results 
show that treatment at either concentration significantly reduced the number of lung 
metastases (Fig. 29A). Moreover, metastases were found in the liver, kidneys, 
spleen, intestines and diaphragm in the control mice but not in the treated mice (Fig. 
29B). Immunohistochemical staining of the subcutaneous tumors demonstrated a 
strong correlation between p-Src and the number of metastases (Fig. 29C), with the 
highest number of metastases found in mice with the highest intratumoral p-Src 
levels.  
 
CRKL is a miR-200 target that mediates integrin-dependent signaling.  
In order to identify the underlying mechanism of how miR-200 regulates the 
Integrin-FAK/Src pathway, we performed a qPCR screen of several integrin 
signaling adaptors in our murine cell lines with altered miR-200 expression levels 
(Fig. 30A and B). Integrin adaptors have been implicated in many cancer types due 
to their importance in transmitting signals from the ECM to intracellular signaling  
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Fig. 28 Migration, invasion & TGFβ response of 344SQ 
and 531LN2 cells are blocked with Src inhibitors. (A) 
Sphere formation of 344SQ in 3D Matrigel cultures. 
Images were taken at day 10 and sphere size and 
invasiveness scored (B). Dasatinib (50 nM) was added at 
day 4, AZD0530 (3 μM) at day 5 and TGFβ (5 ng/ml) at 
day 6. 
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Fig. 29 Dasatinib treatment in vivo affects metastases and phospho-
Src expression. (A) Primary tumor weight and number of lung 
metastases in syngeneic mice treated with dasatinib n=9 (10 mg/kg: 
solid shapes, 20 mg/kg: empty shapes) or vehicle n=10.  (B) Lung 
metastases in the control and treated mice. (C) Distant organ 
metastases found in the control mice (DMSO) as indicated by the black 
arrows. (D) Immunohistochemistry of subcutaneous tumors from 
dasatinib treated or control mice stained for p-Src Y418. The left 2 
columns represent mice with a high number of metastases, the right 2 
columns mice with few or no metastases.  
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Fig. 30 mRNA expression of integrin adaptor 
molecules in the murine cell lines. Quantitative 
RT-PCR analysis in the 393P_ZEB1 vs. control 
cells (A) and 344SQ_200 vs. control cells (B). 
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pathways by acting as a central hub [33]. From this screen we identified CRKL, 
which inversely correlated with the miR-200 levels. CRKL has been identified as an 
oncogene in NSCLC and its overexpression correlates with poor prognosis [36, 38]. 
As an integrin adaptor molecule it plays an important role as a scaffold protein, 
leading to integrin-dependent complex formation especially at sites of focal 
adhesions. Its protein expression in the Itgβ1 knockdown cells (Fig. 13B), the murine 
cell line panel as stratified by EMT status (Fig. 16A & B) and after treatment with 
FAK (Fig. 17A) or Src inhibitors (Fig. 19A) suggested a potential role for CRKL in 
coupling the ECM-integrin signals to the FAK/Src pathway.  
CRKL is a potential miR-200 target, with two predicted target sites in the 3’ 
untranslated region (Fig. 31A). To test whether total CRKL levels are regulated by 
miR-200, and could therefore regulate signaling downstream of Itgβ1, we 
constructed a luciferase reporter containing the CRKL 3’ untranslated region (UTR). 
The luciferase reporter assay confirmed that wild-type CRKL is a direct miR-200b 
and -c target, with mutation of the second predicted seed sequence or both together 
reversing the effect of pre-miR binding (Fig. 31B-D). Functionally, siRNA knockdown 
of CRKL reduced in vitro migration and invasion of H157 cells in Transwell assays 
(Fig. 32A-C) and 3D Matrigel/collagen I cultures (Fig. 33A). The 3D structures 
displayed a more rounded morphology, which was further seen in the adhesion 
assay on fibronectin (Fig. 33B).  Consistent with its role as an adaptor molecule, the 
effect of CRKL was mediated by blockade of FAK and Src localization to focal 
adhesion sites (Fig. 34A), rather than phosphorylation of the FAK/Src pathway. 
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Fig. 31 CRKL is a direct miR-200 b and c target. (A) Prediction 
score of human and mouse CRKL being a miR-200 target using 
Targetscan. (B) Luciferase Reporter Assay in H157 cells using 
hRL_3’ CRKL wt and mutant constructs. * p < 0.05, ** p < 0.03, *** 
p < 0.003 (C) The CRKL 3’UTR contains two predicted miR-
200b/c/429 sites at the indicated locations. Two point mutations 
were introduced in each miR-200 seed sequence (red). (D) Four wt 
or mutant 3’UTR constructs were individually generated and cloned 
into the hRL vector. 
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Fig. 32 CRKL siRNA transfection in H157 cells. (A) CRKL mRNA level 
after transfection with CRKL siRNA SMARTpool (final concentration 
25 nM) compared to control siRNA and untreated cells. (B) Western 
Blot analysis of CRKL siRNA 48 hrs post-transfection using different 
siRNA concentrations. (C) Migration (black bar) and invasion (grey 
bar) of H157 cells using CRKL siRNA. 
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Fig. 33 CRKL siRNA affects 3D invasion and adhesion 
on Fibronectin (A) H157 transfected with CRKL siRNA 
(or control siRNA) grown in 3D Matrigel/collagen I (1.5 
mg/ml) for 9 days. Scale bar is 200 μm. (B) Adhesion 
assay of H157 on Fibronectin transfected with CRKL 
siRNA. 
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Fig. 34 CRKL knock-down affects localization of p-Src and p-
FAK to focal adhesions. (A) Immunofluorescence staining of 
transfected H157 stained for p-Src Y418 or p-FAK Y861. An 
average of 30 cells was counted for positive staining at their 
focal adhesions (FA). Scale bar is 20 μm. 
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In addition to the CRKL siRNA, we used an shRNA-based knockdown 
approach in the mesenchymal 344SQ and 393P_ZEB1 cells. CRKL knockdown in 
the 344SQ cells (Fig. 35A) caused a significant decrease in the phospho-FAK and 
Src levels in shRNA 1 and 2 (Fig. 35B), which affected adhesion on a fibronectin 
matrix (Fig. 35C). Furthermore, the knockdown causes a functional decrease in 
Transwell migration and invasion (Fig. 36A) and a growth disadvantage in 3D 
assays in Matrigel (Fig. 36B). Similar results were obtained in the 393P_ZEB1 cells 
with CRKL knockdown (Fig. 37A), even though the effect on the FAK/Src pathway 
activation was not seen at the biochemical level (Fig. 37B), the functional 
consequences were the same as in the 344SQ cells (Fig. 37C, Fig. 38A and B). The 
effect on the localization of phospho-FAK and Src was confirmed biochemically, 
using a cytosolic and particulate separation approach. CRKL knockdown causes a 
defect in the localization/assembly of the activated FAK/Src complex, as seen by 
Western Blot analysis (Fig. 39A). Those results were further validated by 
immunofluorescent staining of p-Src and p-FAK, which are no longer localized at the 
focal adhesions (Fig. 40A, top 2 panels, and B). In addition, the focal adhesion 
marker Paxillin is mostly localized in the cytoplasm in the CRKL knockdown cells 
and there is no co-localization found of p-FAK and Paxillin at the focal adhesions 
compared to the control cells (Fig. 40A, lower panel, and B). This result confirms that 
CRKL is necessary for proper focal adhesion complex formation. 
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Fig. 35 CRKL knockdown in 344SQ cells causes a 
defect in adhesion. (A) Quantitative RT-PCR and (B) 
Western Blot analysis of 344SQ cells after CRKL-shRNA 
knockdown. (C) Adhesion of CRKL shRNA cells on 
Fibronectin shows a decrease compared to the control 
cells (cells stained with DAPI for the nucleus). 
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Fig. 36 CRKL knockdown in 344SQ cells causes a decrease in 
migration and invasion. (A) CRKL shRNA causes a significant 
decrease in Transwell migration and invasion. (B) CRKL knockdown 
causes a reduction of growth in 3D Matrigel. 
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Fig. 37 CRKL knockdown in 393P_ZEB1 cells causes a defect in 
adhesion. (A) Quantitative RT-PCR and (B) Western Blot analysis of 
344SQ cells after CRKL-shRNA knockdown. (C) Adhesion of CRKL 
shRNA cells on Fibronectin shows a decrease compared to the control 
cells. 
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Fig. 38 CRKL knockdown in 393P_ZEB1 cells causes a decrease in 
migration and invasion. (A) CRKL shRNA causes a significant 
decrease in Transwell migration and invasion. (B) CRKL knockdown 
has a slight effect on the 3D invasion in Matrigel/collagen I. 
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Fig. 39 CRKL knockdown in 344SQ cells causes a 
decrease of activated FAK and Src localized at the 
membrane. (A) Cytosol and particulate separation 
shows a significant decrease in p-FAK, p-Pax, p-Src 
and p-Cortactin in the particulate fraction compared to 
the control cells. Itgβ1 is the particulate control, β-actin 
is the cytosolic control. 
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Fig. 40 CRKL knockdown in 344SQ cells affects localization of activated FAK 
and Src. (A) Immunofluorescent staining for p-Src Y418 and p-FAK Y861 and co-
staining for Paxillin (Pax, for focal adhesions) and p-FAK Y861. Scale bar is 20 
μm. (B) Quantification of p-Src and p-FAK at the focal adhesions and co-
localization of the focal adhesion marker Paxillin with p-FAK. * p < 0.0001 
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Discussion 
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Tumor cell invasion is a complex, multi-step process in which cells acquire a 
mesenchymal phenotype through changes in the expression of transcription factors 
and actin associated proteins (including metallo proteinases necessary to degrade 
the ECM), reorganization of the actin cytoskeleton, as well as changes in the 
regulation of microRNAs. [7] The acquisition of the mesenchymal phenotype is 
thought to occur through an epithelial-to-mesenchymal transition, a developmental 
process which is commonly found in tumor development as well. During the process 
of EMT cells are reprogrammed to increase their migratory and invasive abilities 
along with decreased cell-cell adhesion allowing for the enhanced motility. The miR-
200/Zeb1 axis, through its double-negative feedback loop, has been well established 
as a master regulator of EMT. EMT is also induced by changes in signaling 
pathways (e.g. through mutations) and growth factors such as TGFβ. It is well known 
that the expression of miR-200 is able to prevent the TGFβ-induced EMT. [7, 10] 
Despite the knowledge of miR-200 being a master regulator of EMT, the mechanism 
by how the miR-200/Zeb1 axis regulates the mesenchymal phenotype through 
alterations of cellular functions remains unclear and was the focus of this study. We 
used murine cell lines derived from the well-established KP model as well as human 
lung cancer cell lines to gain a better understanding of the underlying cellular 
alterations. 
In recent years more focus has been on the tumor ECM instead of just the 
tumor cells since cell-intrinsic changes alone have been shown to be insufficient to 
drive an invasive phenotype. In our 3D model we confirm those observations by 
showing that changes in the miR-200 levels alone cells do not become invasive but 
74 
 
hyper-proliferative only when grown in a Matrigel matrix. Similarly, previous studies 
with our KP model showed that TGFβ-induced EMT or EMT induced by matrix 
stiffness is insufficient to produce 3D invasion in a synthetic matrix [44]. This study 
shows that the combination of cell-intrinsic changes and the composition of the 
ECM, in particular the presence of collagen type I, are necessary to drive tumor cell 
invasion. In addition to changes in the expression of several cell-surface proteins 
changes during EMT, it has been shown that the ECM undergoes remodeling during 
tumor progression [45] . Many of those changes are regulated by microRNAs that 
target cell adhesion (e.g. cadherins) and ECM (e.g. collagens, fibronectin) molecules 
[46]. Proteomic and mRNA profiling of cell lines derived from our mouse model 
showed differences in ECM (collagens, laminins) and adhesion molecules when 
comparing non-metastatic to metastatic cells [19], suggesting that miR-200 controls 
both cell-intrinsic changes and changes in the ECM. ECM molecules have been 
shown to be able to induce an EMT signal, for example through the binding of 
collagens to integrins leading to the downstream activation of signaling pathways 
increasing cell motility [8]. The presence of collagen I, found in the ECM surrounding 
tumors, causes the matrix to become stiffer due to its crosslinking abilities and stiffer 
matrices have been associated with increased tumor growth and progression (e.g. in 
breast cancer through modulation of microRNAs) [18] [47]. Our finding that β1-
Integrin-collagen I contact is necessary to drive invasion in 3D cultures supports 
those prior findings and further suggests that the balance cell-cell and cell-matrix 
interactions driven by miR-200 is crucial for the differential response to the ECM. 
75 
 
This study shows that Zeb1 drives enhanced matrix responsiveness which is 
due to an increase in the FAK/Src pathway activation, which is significantly 
decreased in cells with high miR-200 levels.  In order to demonstrate the importance 
of the ECM in regulating intracellular signaling through β1-Integrin-collagen I contact, 
we utilized 2D and 3D in vitro assays in murine and human cells, combined with in 
vivo studies in our well-established KP mouse model to show that the modulation of 
miR-200 on cell-ECM interactions is applicable in a range of different systems. We 
further used pharmacological inhibitors and different knock-down approaches in 
vitro, which caused a significant decrease in 2D and 3D invasion, confirming our 
hypotheses. Previous work has shown that loss of miR-200 drives in vivo 
metastases in our KP model [16], which was significantly decreased upon 
pharmacological inhibition of Src or knock-down of Itgβ1 as shown in this study. As 
previously mentioned, the interaction of cells with the ECM is largely dependent on 
integrins, which further mediate the activation of FAK, yet the exact mechanism of 
the FAK pathway activation remains to be elucidated. It is known that FAK is 
phosphorylated and re-localizes to integrin-mediated focal adhesions in stiffer 
matrices. Once localized at the focal adhesions, it serves as binding partner for Src, 
which further activates FAK and it can bind multiple adaptor molecules, including 
Paxillin and p130Cas [18]. Similar to previous studies in which FAK or Itgβ1 siRNA 
reduced collective cell migration as well as strengthened cell-cell adhesion through 
E-cadherin modulation, we showed here that FAK or Itgβ1 inhibition, 
pharmacologically and by shRNA respectively, caused a significant decrease in cell 
migration and invasion [21]. 
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Due to its important role in EMT, many studies are still trying to understand 
how miR-200 suppresses EMT, particularly which cellular mechanisms are being 
regulated. Recent studies have identified that the miR-200 family directly targets 
multiple actin associated genes, such as moesin, FHOD1, PPM1F, in breast cancer, 
therefore inhibiting metastasis. [48, 49] A study published this year by Goodall et al. 
[50] shows a genome-wide screen in breast cancer cells of miR-200 targets which 
are involved in focal adhesions, invadopodia formation, MMP activity, processes 
required for tumor cell invasion and characteristics of actin dynamics. We have 
shown that CRKL, as published in this study, is a direct miR-200 b and c target and 
functionally effects migration and invasion in lung cancer cells. Our studies have 
identified that temporary CRKL inhibition using siRNA is necessary for the outside-in 
integrin-dependent FAK/Src activation as seen by a decreased localization of 
activated FAK and Src at the focal adhesions. Furthermore, sustained CRKL 
inhibition using shRNA affects the FAK/Src activation at the biochemical level, 
leading to decreased 2D and 3D invasion and defects in fibronectin adhesion. In 
addition, our data suggests that CRKL enhances the inside-out signaling as seen in 
the FAK and Src inhibitor studies, suggesting a feedback loop between CRKL and 
the FAK/Src pathway (Fig. 41).  
This study highlights the importance of the tumor microenvironment, 
specifically collagen I, in mediating the activation of intracellular central signaling 
pathways that drive tumor cell invasion. We have shown that those central pathways 
can be inhibited at multiple levels, making them attractive targets for new combined 
treatment strategies in lung cancer patients.  
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Further studies are needed to identify the effect of CRKL on the FAK/Src 
complex formation at sites of focal adhesions, its downstream effects on actin 
reorganization and finally to determine the role of CRKL in in vivo metastases, due 
to its clinical relevance in predicting survival outcome. 
 
 
Fig. 41 Proposed model of miR-200/Zeb1 
regulating tumor cell activation through β1-
integrin-collagen I interaction. Direct targeting 
of CRKL by miR-200 disrupts the localization 
and activation of the FAK/Src complex at focal 
adhesions leading to a decrease in cell 
migration and invasion. 
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